Cutera, Inc. (NASDAQ:CUTR) has earned an average rating of “Hold” from the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $34.67.

Several equities analysts have weighed in on the company. Zacks Investment Research cut Cutera from a “hold” rating to a “sell” rating in a research note on Wednesday, May 15th. ValuEngine cut Cutera from a “hold” rating to a “sell” rating in a research note on Friday, May 10th. TheStreet cut Cutera from a “c” rating to a “d” rating in a research note on Thursday, February 21st. BidaskClub upgraded Cutera from a “hold” rating to a “buy” rating in a research note on Friday, March 22nd. Finally, Stephens lowered their target price on Cutera from $40.00 to $25.00 and set an “overweight” rating on the stock in a research note on Thursday, February 21st. They noted that the move was a valuation call.

In other news, Director J Daniel Plants acquired 14,011 shares of the firm’s stock in a transaction that occurred on Friday, May 31st. The stock was bought at an average price of $16.93 per share, with a total value of $237,206.23. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have bought a total of 49,522 shares of company stock worth $832,825 over the last quarter. Company insiders own 1.80% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in CUTR. Marshall Wace North America L.P. raised its stake in Cutera by 41.3% in the first quarter. Marshall Wace North America L.P. now owns 5,052 shares of the medical device company’s stock valued at $89,000 after purchasing an additional 1,476 shares in the last quarter. Marshall Wace LLP boosted its holdings in shares of Cutera by 134.5% during the 1st quarter. Marshall Wace LLP now owns 29,994 shares of the medical device company’s stock valued at $529,000 after buying an additional 17,205 shares in the last quarter. Paradigm Capital Management Inc. NY boosted its holdings in shares of Cutera by 96.4% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 834,500 shares of the medical device company’s stock valued at $14,737,000 after buying an additional 409,700 shares in the last quarter. Factorial Partners LLC boosted its holdings in shares of Cutera by 19.2% during the 1st quarter. Factorial Partners LLC now owns 46,500 shares of the medical device company’s stock valued at $821,000 after buying an additional 7,500 shares in the last quarter. Finally, Alambic Investment Management L.P. bought a new stake in shares of Cutera during the 1st quarter valued at $312,000. 91.75% of the stock is owned by institutional investors.

NASDAQ:CUTR traded down $0.13 during trading hours on Wednesday, hitting $17.77. 703 shares of the company traded hands, compared to its average volume of 100,134. The company has a current ratio of 1.66, a quick ratio of 1.09 and a debt-to-equity ratio of 0.20. Cutera has a one year low of $12.32 and a one year high of $44.90. The stock has a market cap of $251.32 million, a PE ratio of -7.95 and a beta of 0.74.

Cutera (NASDAQ:CUTR) last issued its quarterly earnings data on Thursday, May 9th. The medical device company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.30). Cutera had a negative net margin of 22.45% and a negative return on equity of 65.62%. The company had revenue of $36.00 million for the quarter, compared to the consensus estimate of $33.45 million. During the same quarter last year, the business posted ($0.02) earnings per share. Cutera’s revenue was up 5.6% on a year-over-year basis. On average, sell-side analysts forecast that Cutera will post -0.66 earnings per share for the current fiscal year.

Cutera Company Profile

Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.

Featured Article: Conference Calls and Individual Investors

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.